Lantern Pharma Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Lantern Pharma Inc. on January 24, 2022. The company is a Delaware corporation with principal executive offices in Dallas, Texas, and its common stock trades on The Nasdaq Stock Market under the symbol LTRN. The registrant is classified as an emerging growth company.
Key Financial Metrics
This filing is a Current Report regarding a specific corporate event and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. No financial metrics are reported in this document.
Material Changes and Events
Under Item 8.01 (Other Events), the Company announced a significant regulatory milestone:
- The U.S. Food and Drug Administration (FDA) granted rare pediatric disease designation and orphan drug designation for the Company's drug candidate LP-184.
- The designation applies to the treatment of atypical teratoid rhabdoid tumor (ATRT).
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard regulatory context. The press release detailing the FDA designation is included as Exhibit 99.1 but is explicitly stated not to be deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the specific benefits and timelines associated with the FDA rare pediatric disease and orphan drug designations for LP-184.
- Review the full text of the press release (Exhibit 99.1) for details on the clinical development plan for ATRT.
- Check subsequent filings (e.g., 10-Q or 10-K) for financial data, as this 8-K contains no financial figures.